论文部分内容阅读
Enalaprilat(EP)是治疗高血压病的口服血管紧张素转换酶抑制剂。本研究旨在评价非肠道给药治疗高血压的疗效与耐受性。方法采用双盲法评价静脉内 EP 治疗中度(卧位舒张压 DBP 为100～114mmHg)或重度(DBP 为115～130mmHg)高血压病人。研究分基础稳定期与双盲治疗期。将中度高血压病人随机分组,接受静脉内 EP1.25mg 或安慰剂,均每6h1次。如治疗24h 后DBP 低于95mmHg 则认为有效,再以相同剂量治疗24h;无效者 EP 剂量增至5mg,仍每6h1次,持续24h。重度组开始时静注 EP1.25mg 或速尿40mg,每6h1次。12h 后如 DBP 下降少于10mmHg,EP 增
Enalaprilat (EP) is an oral angiotensin-converting enzyme inhibitor for the treatment of hypertension. This study was designed to evaluate the efficacy and tolerability of parenteral administration in the treatment of hypertension. Methods A double-blind evaluation of intravenous EP was used to treat moderate (DBP of 100-114 mm Hg) or severe (DBP of 115-130 mm Hg) hypertensive patients. Study divided into basic stable and double-blind treatment. Moderately hypertensive patients were randomized to receive intravenous EP1.25mg or placebo, each 6h1 times. Such as treatment of 24h DBP less than 95mmHg then considered effective, and then treated with the same dose of 24h; ineffective EP dose increased to 5mg, still every 6h1, for 24h. Severe group began intravenous EP1.25mg or furosemide 40mg, every 6h1 times. After 12h, such as DBP decreased less than 10mmHg, EP increase